Skip to content
Mobidiag logo
Mobidiag
Enabling faster, more accessible molecular diagnostics
  • Home
  • Solutions
    • Respiratory Infections
    • Gastrointestinal Infections
    • Antimicrobial Resistance Management
    • Healthcare Associated Infections
    • Sepsis
  • Products
    • Coronavirus tests
    • Coronavirus solution
    • Amplidiag® RESP-4
    • Novodiag® COVID-19
    • Amplidiag® COVID-19
    • Mobidiag - Novodiag
    • Novodiag® Solution (CE-IVD)
    • COVID-19
    • C. difficile
    • Bacterial GE+
    • CarbaR+
    • Stool Parasites
    • Mobidiag - Amplidiag
    • Amplidiag® Solution (CE-IVD)
    • Amplidiag Easy
    • RESP-4
    • COVID-19
    • H. pylori+ClariR
    • Bacterial GE
    • CarbaR+VRE
    • CarbaR+MCR
    • Stool Parasites
    • Viral GE
    • C. difficile+027
    • LifeSciences (RUO)
    • S7 Fusion Polymerase™
    • Amplidiag® Multiplex PCR Master Mix
  • News
    • Mobidiag News
    • Media
    • Events
    • Blog
  • Literature
    • Publications
    • Posters
    • Presentations
  • Company
    • About Us
    • Quality
    • Board of Directors
    • Management Team
    • Investors
    • Careers
  • Contact
    • Contact Us
    • Worldwide Distributors
  • Log in
  • Log in

News

Expert Review of Molecular Diagnostics , Volume 15, 2015 – Issue 9

August 15, 2015

Differentiating virulent 027 and non-027 Clostridium difficile strains by molecular methods
Silja Mentula, Sanna Laakso, Outi Lyytikäinen, Juha Kirveskari.
Learn more about Amplidiag® C. difficile+027

Share on: Share on FacebookShare on LinkedinShare on Twitter
Posted in: Publications

Post navigation

← Press Release: Mobidiag Announces CE Marking of Novel Helicobacter Pylori and Clarithromycin Resistance Test
Press Release: Mobidiag and Unilabs Enter into Agreement over Use of Amplidiag Product Line for Molecular Gastrointestinal Diagnostics →

Mobidiag Logo

Mobidiag (HQ)

Keilaranta 16 A
FIN-02150 Espoo
Finland

+358 10 5050 770
sales@mobidiag.com

Mobidiag France

172 rue de Charonne
Le Dorian B2
75011 Paris
France

+33 1 55 25 17 00
adv@mobidiag.com

Mobidiag UK

Aston Court, Kingsmead Business Park,
Frederick Place, High Wycombe
Buckinghamshire, HP11 1LA
UK
+44 (0) 333 305 7506
sales@mobidiag.com

Mobidiag Sweden

+358 10 5050 770
sales@mobidiag.com

Site map

  • Home
  • Solutions
    • Respiratory Infections
    • Gastrointestinal Infections
    • Antimicrobial Resistance Management
    • Healthcare Associated Infections
    • Sepsis
  • Products
    • Coronavirus solutions
    • Novodiag® Solution (CE-IVD)
      • COVID-19
        • Novodiag COVID-19
        • Amplidiag COVID-19
      • C. difficile
      • Bacterial GE+
      • CarbaR+
      • Stool Parasites
    • Amplidiag® Solution (CE-IVD)
      • COVID-19
      • H. pylori+ClariR
      • Viral GE
      • CarbaR+VRE
      • CarbaR+MCR
      • Stool Parasites
      • Bacterial GE
      • C. difficile+027
    • LifeSciences (RUO)
      • S7 Fusion Polymerase
      • Amplidiag® Multiplex PCR Master Mix
  • News
    • News
    • Events
    • Blog
  • Company
    • About Us
    • Quality
    • Management Team
    • Board of Directors
    • Investors
    • Careers
  • Literature
  • Contact
    • Contact Us
    • Worldwide Distributors
  • Client Portal
    • Login or Register
    • Edit My Profile

Search

Contact Us

    Privacy Policy
    Copyright © Mobidiag Ltd. All Rights Reserved. Learn more about our Privacy policy.
    Website crafted by Design Reform.
    Top